Ultragenyx製藥 RARE 深 滬
等待開盤 10-30 09:30:00 美东时间
34.59
-0.180
-0.52%
華盛通- 最 高35.77
- 今 開34.53
- 成交量 126.49万股
- 最 低 33.94
- 昨 收 34.77
- 總市值 33.33亿
- 52周最高 53.04
- 市盈率 靜 --
- 換手率 1.31%
- 52周最低 25.81
- 委 比 38.94%
- 總股本 9637.16万
- 歷史最高 179.647
- 量 比 1.06
- 振 幅 5.26%
- 歷史最低 25.81
- 每 手 1
- 風險率 6.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What to Expect from Kiniksa Pharmaceuticals's Earnings
Kiniksa Pharmaceuticals (NASDAQ:KNSA) is preparing to release its quarterly ear...
10-28 03:01
Headwaters Capital falls 2.7% in Q3; adds Driven Brands, exits Bentley Systems
The Headwaters Capital Management, LLC portfolio declined -2.7% during Q3 2025 compared to a +5.3% gain for the Russell Mid Cap Index over the same period. Driven Brands (NASDAQ:DRVN): A new starter p...
10-17 01:05
Tactical Resources Advances Nasdaq Listing Amid Strategic Rare Earth Developments
Tactical Resources Corp. ( ($TSE:RARE) ) has shared an update. Tactical Resourc...
10-17 00:39
ClearBridge SMID Cap Growth Strategy
The ClearBridge SMID Cap Growth Strategy underperformed its Russell 2500 Growth Index benchmark during the third quarter, with the index gaining 10.7%. As such, the performance of SMID growth equitie...
10-13 23:15
聚焦肺癌、心血管疾病治疗，这些创新药将在第八届进博会首秀
10月5日，第八届进博会迎来开幕倒计时30天。多家全球领先的跨国药企和医药展商率先揭晓了将要亮相本届进博会的首秀展品和最新解决方案。 此前，进博局方面介绍，第八...
10-05 09:51
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
Ultragenyx Pharmaceutical Inc. has appointed Eric Olson as Chief Business Officer (CBO) and Executive Vice President, succeeding Thomas Kassberg's retirement. Olson will oversee business development, corporate development, and alliance management. With nearly 20 years of experience in biopharma, Olson has contributed to over $15 billion in transactions, including leading partnerships at Stoke Therapeutics and Alnylam Pharmaceuticals. He expressed...
09-30 20:05
USA Rare Earth Accelerates Mine-to-Magnet Strategy with the Transformative Acquisition of Less Common Metals (LCM)
USA Rare Earth acquires UK-based LCM for $106.7M, solidifying its leadership in rare earth production outside China. The deal enhances USAR's end-to-end supply chain, enabling sustainable rare earth alloy production and recycling capabilities. USAR secures $125M equity investment to accelerate growth. A conference call will discuss the acquisition at 8:30am ET.
09-29 10:05
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
Assessing Ultragenyx Pharmaceutical: Insights From 8 Financial Analysts
In the preceding three months, 8 analysts have released ratings for Ultragenyx ...
09-05 22:01
Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $105 Price Target
Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and maintains $105 price target.
09-05 21:44
